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Daily, or quotidian, hemodialysis continues to garner interest worldwide. The two most common forms in use
are short daily hemodialysis (hemeral hemodialysis) and daily nocturnal hemodialysis. The currently accepted
thrice-weekly dialysis regimen adopted some four decades ago was not designed to provide optimal patient
outcomes, but rather to achieve some kind of compromise between adequacy, patient acceptance and economic
factors. In the last decade, a number of observational studies have unanimously demonstrated multiple clinical
benefits with more frequent dialysis. This paper reviews some important methodologic aspects of quotidian
dialysis delivery and the outcomes literature in this field, including economics. [Hong Kong J Nephrol 2004;6
(1):14–21]
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INTRODUCTION
Daily, or quotidian, hemodialysis continues to garner
interest worldwide. The two most common forms in
use are short daily hemodialysis (SDHD), also termed
hemeral  hemodialysis ,  and dai ly  nocturnal
hemodialysis (DNHD). Although these are the most
popular forms in use, hybrids exist as well. Both are
commonly used as home-based therapies, even though
they can also be administered in dialysis centers.
The currently accepted thrice-weekly dialysis
regimen adopted some four decades ago was not
designed to provide optimal patient outcomes, but rather
to achieve some kind of compromise between adequa-
cy, patient acceptance (i.e. convenience), and economic
factors. Unfortunately, this occurred despite clear
evidence that there is a strong relationship between
patient outcomes and delivered dialysis dose. In the last
decade, a number of observational studies have
unanimously demonstrated multiple clinical benefits
with more frequent dialysis. The greatest barrier to the
popularization of quotidian dialysis has been the lack
of appropriate funding mechanisms in most developed
countries, so it remains largely experimental. Despite
this obstacle, there appears to be a growing number of
centers wishing to establish their own programs, and
the quotidian dialysis community continues to grow.
This paper reviews some important methodologic
aspects of quotidian dialysis delivery and the outcomes
literature in this field, including economics.
A RATIONALE FOR DAILY DIALYSIS
Over the last decade, there has been great interest in
studying the effect of dialytic dose on patient outcomes.
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This rests on the notion that a greater dialytic dose
results in greater solute removal and this, in turn, results
in improved patient outcomes. Attempts to increase
dose delivery in conventional, thrice-weekly hemodi-
alysis by prolonging treatment time and increasing
dialysis efficiency with higher blood flow rates and
high-flux membranes did not result in improved overall
survival in the HEMO study [1]. Interest has since
turned to the effect of increasing dialysis frequency.
The rationale for daily dialysis is best understood
by considering the difference in solute removal achieved
by delivering the same number of hours of dialysis per
week divided over 6 versus 3 days, (e.g. 6 = 2-hour
versus 3 = 4-hour treatment sessions). It is known that
most of the urea (up to 75% with very high efficiency
dialysis membranes) is removed during the first 2 hours
of a 4-hour dialysis treatment [2]. This is explained
by the fact that the serum urea concentration falls
logarithmically over time, and as it falls, the concen-
tration gradient across the dialysis membrane similarly
falls, thus limiting the rate of solute removal over time.
Indeed, for this reason, the conventional dialysis
regimen has been described as “self-extinguishing” [3].
This is largely accounted for by the delay in the
diffusion of solutes from various compartments into
the blood compartment or solute disequilibrium. This
phenomenon accounts for the rebound in solute
concentrations that is seen in the post-dialytic period.
Its magnitude varies from one solute to another.
The relative benefits of frequent short and long
hemodialysis regimens are best illustrated by separately
considering the effects of increased dialysis frequency
and dialysis time on the removal of various solutes [4].
Small solutes that diffuse easily across compartmen-
tal barriers (such as urea) are rapidly removed during
dialysis. For the reasons described above, increasing
the time on dialysis will not result in much incremental
benefit in removing such solutes. Increasing dialysis
frequency, however, capitalizes on the fact that more
time is spent on dialysis while the blood solute con-
centrations are high (i.e. in the post-rebound state). In
the first few weeks of SDHD, however, there is a
progressive fall in the predialysis levels of small solutes
until a new steady-state is reached, where overall net
solute removal is lower than in the first week. This is
the case for solutes such as potassium, H+, creatinine,
and urea [5]. Thus, quotidian hemodialysis results in
lower overall time-averaged levels for these solutes over
the week, and smaller oscillations in their levels, thus
overcoming dialysis “unphysiology” as first described
by Kjellstrand et al in the early 1970s [6]. This effect
of increased frequency is found with both SDHD and
DNHD regimens.
Other low-molecular weight solutes that exhibit a
large degree of disequilibrium can also be rapidly
cleared from the blood compartment during dialysis.
The combination of these characteristics results in a
rapid decline in the serum concentration and impedes
effective removal of such a solute during dialysis. The
prototypic molecule in this group is phosphate [7]. Time
is required for inter-compartmental shifting to occur,
so this substance is cleared in a time-dependent fashion.
The removal of greater molecular weight solutes
(e.g. `2-microglobulin and other middle molecules) is
limited by the inefficiency of their removal from the
blood compartment, so disequilibrium becomes less
important. For such substances, membrane flux and
surface area, as well as time, are the principal deter-
minants of net removal. Longer dialysis therefore of-
fers the added advantage of increased phosphate and
middle molecule clearance [8].
Finally, it is also recognized that increased dialysis
frequency may result in a reduction in intradialytic fluid
gains (provided the daily fluid intake remains constant,
which is not always the case). This requires that less
volume is removed per treatment session, and should
thus facilitate fluid removal. This has obvious benefits
for patients with massive fluid gains or other reasons
for intradialytic hypotension. Although on the one hand,
large ultrafiltration volumes result in greater solute
clearance, it is also known that over-hydration and large
volume shifts are associated with deleterious effects
on cardiovascular health such as promoting left ven-
tricular hypertrophy (LVH).
DOSE QUANTIFICATION IN QUOTIDIAN DIALYSIS
The single-pool and equilibrated models (spKt/V and
eKt/V, respectively) used for dose quantification in
conventional dialysis are not validated for use in
frequent dialysis regimens. Because these models do
not take dialysis frequency or efficiency into account,
they cannot be used to compare conventional with
quotidian dialysis regimens. Various models have been
designed to measure delivered dose independently of
frequency of treatment. These include the continuous
equivalent of intermittent clearance derived by Casino
and Lopez [9], the normalized Kt/V proposed by
Depner [3], and the standard Kt/V (stdKt/V) proposed
by Gotch [10]. Suri et al have compared the stdKt/V
with various conventional models [11], but no study
has yet correlated any of these newer measures with
patient outcomes.
Current US National Kidney Foundation – Dialysis
Outcomes Quality Initiative guidelines suggest a
conventional dialysis dose of 1.2 spKt/V per session or
2.0 stdKt/V per week; these are both equivalent to a
daily session eKt/V of 0.38. While maintaining the same
weekly hemodialysis time but performing treatments
daily, Suri et al found that the weekly stdKt/V increased
to about 3. DNHD can provide a higher dose of dialysis
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than any other outpatient dialysis modality (spKt/V
about 2.0 per daily session or weekly stdKt/V > 5) [12].
METHODOLOGY
Patient selection
The primary prerequisite for enrollment in a quotidian
dialysis program is patient willingness, coupled with
either the ability to perform the dialysis procedure or a
willing and able partner. While there may be a tendency
to offer quotidian dialysis to younger, healthier patients
(with the hope of offering them the best possible
outcome), others have used it across all patient groups
regardless of comorbidity. Indeed, in a recent study by
Ting et al, 42 conventional hemodialysis patients with
high levels of comorbidity were switched to SDHD and
followed prospectively with respect to quality of life
(QOL) and other outcomes [13]. These patients, with
an average of four comorbid factors each, showed
significant improvements in QOL as measured by a
validated kidney disease-specific questionnaire, as
well as reductions in erythropoietin (EPO) and anti-
hypertensive medication use. Quotidian dialysis has
been used as salvage therapy for patients with refractory
problems such as malnutrition, hypertension, heart
failure, and metabolic bone disease [14].
Materials and equipment
The technical aspects of quotidian dialysis delivery have
been extensively reviewed elsewhere [15], thus only a
brief review is presented here. Any dialysis machine
suitable for administration of conventional hemodi-
alysis can safely be used for the delivery of SDHD or
DNHD, either at home or in-center. However, a num-
ber of new machines are currently being developed and
evaluated for home quotidian dialysis [16,17]. It is
hoped that these will be more user-friendly (automat-
ed, self-cleaning) and compact than standard ma-
chines. Machines with dual pumps that allow for single-
needle vascular access are gaining popularity. These
may be particularly useful in slow, long, nocturnal dialy-
sis, where clearance is not compromised by the slower
blood flows that they require.
Currently, there are no data to support the use of
one kind of dialysis membrane over another in quotidian
dialysis. Generally speaking, most centers have used
high-flux membranes, and some have even used
pediatric membranes [12]. Dialyzer reuse has been
described, but has largely been abandoned with the fall
in prices of dialysis membranes [18].
Reverse osmosis water purification systems are
becoming increasingly compact, and remain the most
commonly used form of water treatment in the home
dialysis setting. De-ionization is occasionally required,
depending on local water quality. Ultrapure dialysate
has also been used in some programs and can be
considered when a concern about water quality exists
[15,19]. While water treatment systems for SDHD can
be located in the room where the treatment is performed,
noise precludes the use of this setup for patients who
perform dialysis while sleeping. Thus, remote instal-
lation is preferred.
Dialysis prescription
For SDHD, blood and dialysate flow rates are similar
to those used in conventional dialysis. For DNHD, the
blood flow can be reduced to 200–300 mL/min and the
dialysate flow to 100–300 mL/min.
Dialysate composition for SDHD typically does not
change when switching from conventional dialysis.
For DNHD, dialysate composition must be individ-
ualized, particularly with respect to calcium and phos-
phate content. A typical composition includes sodium
140 mEq/L, potassium 2 mEq/L, bicarbonate 32 mEq/L,
and calcium 3–3.5 mEq/L (1.5–1.75 mmol/L), and
usually contains phosphate 1–2 mg/dL (see below).
Commonly, patients receiving DNHD eventually
have low predialysis phosphate levels. If this persists
after discontinuing phosphate binders and liberalizing
dietary phosphate intake, then phosphorus must
be added to the dialysate. Preparations such as
Fleet Phospho-Soda® and Fleet Enema® (Fleet Phar-
maceuticals, Lynchburg, VA, USA) have been used
and can be added to either the acid or bicarbonate
concentrates by the patient. The ideal dialysate calcium
concentration for an individual patient will vary with
dietary calcium intake, supplemental calcium (in the
form of phosphate binders), vitamin D analog use, and
the level of parathyroid gland activity. Occasionally,
measurement of pre- and postdialysis total or ionized
calcium levels can help identify an ideal calcium
concentration. This is discussed in more detail below.
Both SDHD and DNHD may be performed using
standard heparin protocols. DNHD cannot be per-
formed without anticoagulation since this would re-
quire intermittent flushes of normal saline during the
night, but this is feasible in SDHD while the patient
is awake.
Vascular access
With few exceptions, vascular access planning for
quotidian dialysis patients is the same as for conven-
tional hemodialysis patients. Arteriovenous fistulas are
the preferred form, followed by grafts and central
venous catheters. The buttonhole technique has gained
popularity among quotidian dialysis programs. This
involves reusing two out of three needle sites on a
rotating basis, with eventual tract formation that allows
the use of blunt needles [20]. This has been shown to
improve patient comfort and may improve access
longevity. The single-needle technique has also been
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used in DNHD and offers the potential for improved
safety and enhanced access survival.
Safety issues
Many innovations have added to the safety of home
quotidian dialysis. For patients using central venous
catheters, a modified catheter cap known as the
InterLink® system (Baxter Healthcare Corporation,
Deerfield, IL, USA) has been used to prevent air em-
bolism.
Special precautions are required for patients
dialyzing during sleep. Clam-shell locking boxes have
been devised to prevent catheter-tubing connections
separating during DNHD. Moisture sensors and
enuresis alarms have been used to detect leaks around
the machine and around the needle insertion sites,
respectively. Finally, live remote monitoring by
modem/internet has been used to ensure that patients
respond to machine alarms. Monitoring personnel
typically contact the patient by telephone when there
is a problem. While this technology may be useful in a
new program during the learning and development
phaes, many experienced programs have abandoned
this form of monitoring without any complications thus
far.
OUTCOMES IMPROVED BY QUOTIDIAN DIALYSIS
Over the last decade, there has been a growing body of
literature demonstrating marked improvements in
various intermediate outcomes. These include, but are
not limited to, cardiovascular parameters such as LVH
and hypertension, anemia management, metabolic bone
disease, nutritional indices, and QOL.
Cardiovascular parameters
Numerous studies have established that both SDHD and
DNHD result in a rapid reduction in blood pressure.
While some of the observed benefits occur within the
first 2 weeks of quotidian dialysis therapy, others have
noted gradual improvements as long as 1 year after
initiation of quotidian dialysis [21]. The number of
antihypertensives needed decreases significantly by
50% to 90% [19,22].
The mechanism by which blood pressure control
is achieved in quotidian dialysis is likely to be
multifactorial. While it has long been presumed that
volume control is at the heart of this phenomenon, it
has recently become clear that patients undergoing
DNHD can experience improvements in blood pressure
without necessarily experiencing reductions in
extracellular fluid volume as measured by bioelectrical
impedance [21]. Recent work by Chan et al found
improvements in blood pressure in DNHD-treated
subjects in association with reductions in peripheral
resistance and in circulating neurohormonal factors
including norepinephrine [23].
LVH correlates with mortality in patients on chro-
nic hemodialysis. Volume overload, anemia, and hy-
pertension are known potent stimuli for the develop-
ment of LVH. Both SDHD and DNHD promote
improvements in left ventricular geometry and left
ventricular mass [24,25]. These changes have been
attributed to improvements in blood pressure control
[26] and anemia management [27], though again,
neurohormonal factors cannot be excluded. Using a
double cross-over design, Buoncristiani et al showed
that switching patients from conventional hemodialysis
to SDHD and back again resulted in regression of LVH
(measured by left ventricular mass index) followed by
recurrence on resumption of conventional therapy [28].
The strongest correlate of LVH in this study was ex-
tracellular fluid volume, supporting the view that vo-
lume is important in promoting LVH in hemodialysis
patients. Finally, patients with symptomatic heart fail-
ure have benefited from DNHD, both with respect to
symptoms and improvements in ejection fraction [29].
Anemia management
The numerous studies reporting outcomes in anemia
management in quotidian dialysis have yielded an array
of conflicting results. The primary outcomes of interest
in this area have been EPO utilization and achievement
of recommended hemoglobin targets. Some studies
have reported improvements in achieved hemoglobin
level with between 30% and 40% reductions in EPO
requirements [22,27,30]. In our own reported expe-
rience at Humber River Regional Hospital (HRRH),
patients receiving DNHD did not initially show any
reduction in EPO requirements, but this was seen in
association with low ferritin and transferrin saturation
[12]. In a subsequent report, we demonstrated that
intravenous iron supplementation was required before
reductions in EPO requirements could be achieved
[19,31]. The London Daily/Nocturnal study failed to
show any significant reduction in EPO utilization and
attributed this finding to increased blood loss (in the
dialysis circuit) in quotidian dialysis subjects [32].
Nutritional indices
Nutritional status impacts substantially on survival in
the end-stage renal disease (ESRD) population. Mea-
sures such as the protein equivalent of total nitrogen
appearance (nPNA), cholesterol, and serum albumin
have been shown to predict outcomes, and all are
significantly improved by quotidian dialysis. To date,
studies assessing nutritional parameters in quotidian
dialysis have been small. However, despite this, some
interesting observations have been made.
The London Daily/Nocturnal study found increases
in albumin and arm muscle area in SDHD subjects, but
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not in those undergoing DNHD [33]. Unfortunately, in
this small study, two of 10 patients in the DNHD group
were particularly sick during the study, and their low
albumin levels had a negative impact on the overall
group mean. Another small study, however, did find
improvements in nPNA as well as cholesterol in DNHD
subjects [34]. These changes are attributable to
increased appetite, with increased caloric and protein
intake. Although amino acid losses in the dialysate are
expected to be higher in DNHD [35], total body ni-
trogen, as measured by in vivo neutron activation
analysis, was found to remain stable over a 2-year peri-
od [36]. In essence, these changes are not surprising, giv-
en that anorexia is one of the earliest and most readily
treated symptoms improved by more frequent dialysis.
Studies of body composition have shown favorable
results in quotidian dialysis patients as well. Bio-
electrical impedance has emerged as a convenient,
noninvasive and accurate pool for assessing body
composition including body-cell and fat-free mass. The
bioimpedance parameter known as phase angle (which
is related to body-cell mass) is known to correlate
positively with survival in dialysis patients [37], and
some recent work from our center has found this num-
ber to increase progressively over time in patients
undergoing DNHD [38]. The effects these changes have
on survival await further evaluation in larger prospec-
tive studies.
Quality of life
Dialysis is associated with substantial loss of QOL. The
London study collected detailed QOL information using
the generic Medical Outcomes Survey Short Form (SF-
36) and the global Health Utilities Index (HUI), both
of which have been validated for use in the dialysis
patient population. Improvements in many symptoms
were attributable to better fluid management, includ-
ing less cramping on dialysis, fewer headaches, less
symptomatic hypotension, and less dyspnea [39]. HUI
results showed that quotidian dialysis patients
maintained functionality throughout the study period,
while control patients manifested a significant loss.
Indeed, 40% of patients unemployed while on con-
ventional dialysis were able to return to full-time em-
ployment after switching to quotidian dialysis. Depres-
sion scores have been shown to improve in other quo-
tidian hemodialysis studies [40].
Various other methods including the standard
gamble, the time trade-off technique, and measurement
of time to recovery after a dialysis session have also
been evaluated, all favoring quotidian over conventional
dialysis [39,41,42]. Even in patients with high levels
of comorbidity, Ting et al found that SDHD resulted
in improvements in a number of QOL parameters,
including sexual function, sleep, physical functioning,
and general health [13]. Perhaps the most striking
observation is that quotidian dialysis patients freely
choose to carry out their treatments on a near-daily basis
despite the cumbersome and time-consuming nature of
their therapy, the medicalization of their households,
and the inconvenience to their families. The potential
for social and vocational rehabilitation alone are
compelling arguments in favor of the widespread use
of quotidian dialysis.
Metabolic bone disease, calcium, and phosphate
The management of metabolic bone disease in ESRD
is complex and requires frequent manipulation of drug
regimens and diet. By virtue of its increased overall
treatment time, DNHD, in particular, substantially
ameliorates phosphate control [43]. Significant phos-
phate depletion has been observed despite liberaliza-
tion of dietary phosphate intake and elimination of
phosphate binders. This has required phosphate sup-
plementation in the dialysate in order to prevent osteo-
malacia and symptomatic hypophosphatemia.
In DNHD, calcium depletion is also a potential
problem. Using a standard bath calcium concentration
of 1.25 mmol/L, the London group noticed progressive
rises in intact parathyroid hormone (PTH) levels that
were refractory to large doses of vitamin D analog
therapy [44]. These patients had been taken off all
calcium-based phosphate binders because of normal-
ization of serum phosphate levels. This hyperparathy-
roidism was readily reversed by increasing the dial-
ysate calcium concentration to 1.75 mmol/L. Subse-
quent mass balance studies showed that DNHD result-
ed in a net calcium loss of 2 mmol/hour when a bath
concentration of 1.25 mmol/L was used, while a gain
of 3.7 mmol/hour was observed with a 1.75 mmol/L
bath concentration. The combination of a standard
(low) dialysate calcium concentration with loss of oral
calcium intake due to the elimination of calcium
carbonate-based phosphate binders resulted in sig-
nificant calcium depletion and hyperparathyroidism. A
study from HRRH found that an average bath calcium
concentration of 1.6 mmol/L helped to maintain or
improve the bone mass of patients, as measured yearly
using dual-energy X-ray absorptiometry densitome-
try, and suppressed PTH to the normal range. This may
have been the cause of the low bone turnover diagnosed
by bone-marrow biopsy in nine of 15 patients. This
suggests that the calcium level in the dialysate may need
to be adjusted according to the needs of the patient.
This was achieved at HRRH through the addition of
powdered calcium chloride by the patient at specifically
prescribed amounts.
With a substantial reduction in phosphate levels
achieved with DNHD, and to a lesser extent with
SDHD, there is a net reduction in the calcium/phospho-
rus product. This parameter is associated with metasta-
tic calcification and increased mortality. Interestingly,
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DNHD has been reported to cause dissolution of extra-
osseous calcification [45]. Overall, it appears that the
net effect of quotidian dialysis on calcium and phos-
phate metabolism is favorable, provided that appro-
priate changes are made to the dialysate composition
and patients are followed for the development of hyper-
parathyroidism.
Sleep disturbances
Sleep abnormalities remain highly prevalent in the
ESRD population and are associated with poor QOL
and increased mortality [46,47]. Baseline sleep studies
were performed in 14 subjects in the Toronto Study
[48]. In the eight patients with obstructive sleep apnea,
conversion to DNHD normalized the frequency of
apnea/hypopnea episodes from 46 ( 19 to 9 ( 9 per
hour (p < 0.006), and resulted in normalized oxygen
saturation during sleep. Despite these changes, another
study failed to show any reduction in daytime sleepiness
with DNHD as measured by the multiple sleep latency
test [49]. The effect of SDHD on sleep apnea is un-
known.
Uremia is associated with impaired autonomic
regulation. The impact of DNHD on nocturnal cardiac
autonomic outflow has also recently been evaluated
by our group. We performed heart rate variability anal-
ysis during stage 2 sleep in nine ESRD patients on
conventional hemodialysis and 6 to 15 months after
conversion to DNHD. DNHD was associated with a
reduced duration of nocturnal hypoxemia and restored
the normal balance between sympathetic and parasym-
pathetic modulation of heart rate [50].
ECONOMIC ISSUES IN QUOTIDIAN DIALYSIS
The financial implications of daily dialytic therapy
probably vary significantly when comparing home with
in-center treatment. Today, most available data come
from home daily dialysis studies.
Potential sources of cost savings
Since home dialysis relies on self administration of
therapy, there is an obvious and substantial reduction
in nursing and technical support staff costs. Reductions
in antihypertensive medications, EPO, phosphate
binders, hospitalizations, and vascular access interven-
tions also hold significant potential for cost reduc-
tion either to the dialysis program itself and/or to the
health care system at large.
Sources of increased expenditure
The main upfront costs for home quotidian dialysis
include dialysis machine purchase and installation as
well as installation of water supply and purification
systems. Moreover, it includes the expense of training
the patient. Thereafter, longitudinal costs in disposable
materials, including dialysate, dialysis membranes
and tubing, increase in proportion to the frequency of
treatment.
Balancing costs and savings
The most detailed economic analyses to date in the area
of home quotidian dialysis come from the London
(SDHD and DNHD vs conventional) and HRRH
(DNHD vs conventional) programs. A prospective de-
scriptive economic analysis by McFarlane et al (HRRH)
showed that home DNHD was associated with a
CAN$13,000/patient/year reduction in total health care
costs when compared with conventional in-center
hemodialysis [51]. In the London experience, for any
given year of follow-up, no significant differences be-
tween SDHD, DNHD, and conventional in-center
dialysis were noted [41]. However, when total treatment
costs for the first year on quotidian dialysis were com-
pared with the previous year’s costs on conventional
therapy, switching to SDHD and DNHD resulted in
a US$7,171 and US$12,782 per-patient cost saving,
respectively. Remaining on conventional in-center
dialysis, however, resulted in a US$2,247 increase in
total costs for 1 year. This analysis did not take into
account the 40% of patients who were able to return to
full-time employment after switching to quotidian
dialysis and the benefit to society that this confers.
The situation for in-center dialysis is more com-
plicated. Increasing the total volume of dialysis treat-
ments in a given center can place significant strains on
system resources, including personnel and disposable
materials. It is hoped, but not yet proven, that any ad-
ditional costs incurred with daily in-center dialysis
would be offset either financially by reductions in hos-
pitalizations, consultations, investigations, and other
treatments, or otherwise by improving QOL and other
outcomes while accepting increased costs. This has been
shown in a retrospective study by Mohr et al, but pro-
spective studies are needed [52].
Unfortunately, dialysis programs in most countries
often operate near the maximum cost per quality-
adjusted life-year gained that society is prepared to pay.
Furthermore, financial data obtained from one practice
setting may not be generalizable to another. Thus, pro-
grams, or at least countries with varying health care
funding mechanisms, may benefit from locally perform-
ing small economic feasibility studies prior to embark-
ing on large-scale implementation of in-center quotidian
dialysis programs.
FUTURE DIRECTIONS IN QUOTIDIAN DIALYSIS
As can be seen from the preceding discussion, quotidian
dialysis improves numerous intermediate outcomes that
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are themselves associated with increased survival in
the dialysis population. It therefore seems reasonable
to expect that quotidian dialysis will indeed be shown
to reduce mortality in patients who require dialysis. To
date, however, quotidian dialysis studies have been
small and, thus, underpowered to detect survival dif-
ferences, but larger-scale North-American-based
studies are currently underway and may ultimately
resolve this issue. These include a prospective, ran-
domized, controlled trial comparing in-center SDHD
with conventional hemodialysis, and another compar-
ing home-DNHD with in-center conventional hemo-
dialysis. Although these are not necessarily survival
studies per se, they may serve as feasibility studies
to determine whether or not a larger-scale survival
study is warranted. Additionally, an International
Quotidian Dialysis Registry, which will begin collec-
ting data by mid-2004, will be used to collect descrip-
tive data on quotidian dialysis patients worldwide and
will provide data for a matched cohort-controlled sur-
vival study using conventional dialysis patients listed
in other large registries as controls [53]. Both of these
are US National Institutes of Health-endorsed initia-
tives. The Registry is also endorsed by the International
Society for Hemodialysis. The results of these studies
are eagerly awaited.
CONCLUSIONS
SDHD and DNHD are emerging cost-effective treat-
ment modalities that are associated with improve-
ments in many important clinical outcomes including
cardiovascular health, nutrition, and QOL. Although
many advocates for quotidian dialysis believe that
existing data should justify making these treatments
widely available through appropriate funding
mechanisms, it is unlikely that policies will change on
a large scale until improvements in hard outcomes are
established. At present, ongoing research initiatives
strive to delineate a clear role for these promising
therapies. In the interim, it is hoped that dialysis
programs with sufficient interest and resources will
make these treatments available to patients who may
benefit from them the most. In the next decade,
quotidian dialysis will probably find its appropriate
place in the dialysis modality mix, and may represent a
great advancement in the ongoing endeavor to improve
outcomes for patients who require dialysis.
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